Science & Teaching

Study of human medicine

at the Paracelsus Medical Private University – teaching with focus on oncology

The education of students at the Paracelsus Medical Private University (PMU) is an integral part of Univ’s work. Clinic for Internal Medicine III and a special concern of the entire clinic, with the emphasis on the teaching of general pathophysiology in the 3rd century. Year of study and clinical training in the 4th and 5. Year of study.

1. Year of study

Teachers of oncology take part as tutors in the Beginner Seminar of the students at the beginning of their studies. The aim is to provide a basic understanding of medical issues and problem-oriented learning (POL).

2. Year of study

Univ participates in the Physiology Lecture. Clinic for Internal Medicine III is already teaching about the hematopoietic system and uses practical examples to create an idea of patient-related issues. Furthermore, a perspective on the direct networking of basic scientific principles with clinically relevant problems is to be imparted.

3. Year of study

III Medicine will give its main lecture as part of the lecture series on clinical pathophysiology. Over a period of several weeks, basic scientific and clinical questions are combined and the most important clinical pictures are systematically discussed. Using one of Priv-Doz’s. Dr. Alexander Egle’s concept is to introduce patients to clinical problems and frequently occurring situations in a timely manner using a small group-based subset.

4. Year of study

As part of the clinical internships, the students go through the numerous special outpatient clinics and wards of our department in groups of 2 to 3 people on the basis of standardized tasks with the aim of solving patient-oriented questions. Here, the main focus is on the recognition of clinical emergencies and issues that are common for the well-trained general practitioner. In the afternoon, the students are taught alternately by the various departments of internal medicine, with the focus of our clinic on changes in blood counts and oncological as well as infectious diseases.

5. Year of study

In the final year of their studies, students can complete parts of their clinical year (KPJ) at our clinic. The offer of Internal Medicine III is especially aimed at students who show a special motivation and deep interest in our field.

Clinical Practical Year (KPJ)

All students at the Austrian or German universities can spend part of their clinical practical year at our clinic, which is necessary as part of the clinical training. During these weeks, the students will get to know the clinical routine and deepen their practical skills. It is planned that the students, under the supervision of the station-leading specialists, statute patients independently, perform simple punctures, take part in tumor board meetings, present facts in the morning meeting and much more. The Salzburger Landesklinik provides for financial compensation and helps with accommodation and administration.

Rotary doctors program - Information

The training of young doctors as part of the rotation is an integral part of Univ’s work. Department of Internal Medicine III.

We would like to familiarize you with the subjects oncology, haematology, infectiology and rheumatology. During your training at our department, you will receive, among other things, training on the following topics:

Enrolment in transfusion medicine

  • Training on Paravasate and Port-A-Cath Handling
  • Presentation of the aplasia station with introduction to the hygienic measures of reverse isolation.
Our rotating physician representative, Dr. Susanne Steinkirchner (Oncological Bed Station B) and Dr. Matthias Skocic (Infect Outpatient Clinic), will look after you at our department during your cycle and will be at your disposal as a contact person.

You also take part in our training programme as a rotating physician, whether as part of our daily inhouse morning meetings, the special weekly rotary training courses (each on Tuesdays), the interdisciplinary tumor boards or our weekly department seminars.

Due to the successful establishment of IV and cytonurses in our department, a lot of medical working hours could be freed up, which now benefits the regular participation in the rounds as well as the curve visit, and a medical organizational assistant actively supports the administrative activities. A wide-ranging inernistic field is waiting for you. We look forward to welcoming you to our team!

You can find out how to apply as a rotating physician at the Salzburger Landeskliniken at:

http://salk.at/11656.html

Habilitations

Congratulations!

Priv.-Doz. Dr. Lukas Weiss

Paracelsus Medizinische Privatuniversität Salzburg
Prognostische Faktoren bei reifen lymphatischen B-Zell Neoplasien, Salzburg, am 14. November 2017.

Priv.-Doz. Dr. Thomas Melchardt

Paracelsus Medizinische Privatuniversität Salzburg
Prognosis after first line treatment and biology of relapse in Diffuse large B-cell lymphoma, Salzburg, am 04. Dezember 2016.

Priv.-Doz. Dr. Sigrun Ressler

Paracelsus Medizinische Privatuniversität Salzburg

Biomarkers in Cancer and Aging, Salzburg, am 01. Dezember 2015.

Priv.-Doz. Dr. Lisa Pley­er

Pa­ra­cel­sus Me­di­zi­ni­sche Pri­vat­uni­ver­si­tät Salz­burg

Hy­po­me­thy­la­ting agents for tre­at­ment of el­der­ly pa­ti­ents with ag­gres­si­ve mye­lo­id neo­plasms, Salz­burg, am 10. No­vem­ber 2015.

Priv.​Doz.​Dr. Georg Hop­fin­ger

Pa­ra­cel­sus Me­di­zi­ni­sche Pri­vat­uni­ver­si­tät Salz­burg

Sal­va­ge The­ra­pie von ag­gres­si­ven Non-Hodg­kin Lym­pho­men, Salz­burg, 14. Ok­to­ber 2014.

Priv.Doz. Dr. Florian Hohla

Paracelsus Medizinische Privatuniversität Salzburg

Experimentelle Tumortherapie mit GHRH- und BN/GRP-Antagonisten sowie zytotoxischen Somatostatinanaloga, Salzburg, am 29. April, 2014.

Priv.​Doz. Dr. Jutta Au­ber­ger

Pa­ra­cel­sus Me­di­zi­ni­sche Pri­vat­uni­ver­si­tät Salz­burg

In­va­si­ve Schim­mel­pilz­in­fek­tio­nen bei im­mun­kom­pro­mi­tier­ten Pa­ti­en­ten in der Hä­ma­to­lo­gie: Ri­si­ko­fak­to­ren, Durch­bruchs­in­fek­tio­nen und Re­sis­tenz­ent­wick­lung, Salz­burg, am 29. April 2014.

Priv.-Doz. Dr. Tanja N. Hart­mann

Pa­ra­cel­sus Me­di­zi­ni­sche Pri­vat­uni­ver­si­tät Salz­burg

Ad­hä­si­ons­mo­le­kül und Che­mo­kin-Re­zep­tor ver­mit­tel­te In­ter­ak­tio­nen von Tu­mor­zel­len mit dem Mi­kro­mi­lieu. Salz­burg, am 02. Juli 2013.

Priv.Doz. Dr. Olaf Merkel

Paracelsus Medizinische Privatuniversität Salzburg

Challenges in high risk lymphoma: p53, microRNAs and novel substances, Salzburg, am 05. November 2015.

Priv.​Doz. Dr. Jo­han­nes Clau­sen

Me­di­zi­ni­sche Uni­ver­si­tät Inns­bruck

Die Rolle von Na­tür­li­chen Kil­ler-Zel­len in der hä­ma­to­poe­ti­schen Stamm­zel­len­trans­plan­ta­ti­on, Inns­bruck, am 10. No­vem­ber 2011.

Priv.-Doz. Dr. Brigitte Mlinerisch

Paracelsus Medizinische Privatuniversität Salzburg

Die System-Therapie (Medikamentöse Tumortherapie) des Mammakarzinoms. Salzburg, am 06. Juli 2010.

Priv.Doz. Dr. Maria De Santis

Paracelsus Medizinische Privatuniversität Salzburg

FDG PET für die Beurteilung post-chemotherapeutischer Seminom-Residuen. Salzburg, am 07. Oktober 2008.

Priv.Doz. Dr. Ingeborg Tinhofer

Paracelsus Medizinische Privatuniversität Salzburg

Interaktionen von Tumorzellen und Immunzelllen als neues therapeutisches Ziel in der chronisch lymphatischen Leukämie, Salzburg, am 06. April 2006.

Priv.-Doz. Dr. Alexander Egle

Paracelsus Medizinische Privatuniversität Salzburg

Addressing the role of apoptosis-regulation in the establishment of lymphoma in murine models, Salzburg, am 30. Jänner 2006.

Dissertants

Congratulations!

2017

Ca­ta­ko­vic Kemal

Pa­ris-Lo­dron Uni­ver­si­tät Salz­burg

Ex­haus­ti­on and tumor sup­port of T cells in chro­nic lym­pho­cy­tic leu­ke­mia

2016

Hutterer Evelyn

Paris-Lodron Universität Salzburg

The interplay of DNA methylation, trisomy 12 and integrin regulation in the pathophysiology of chronic lymphocytic leukemia

Krenn Peter

Paris-Lodron Universität Salzburg

Contribution of cytoskeleton regulating molecules to chronic lymphocytic cell survival and proliferation

Sifft Eve­li­ne

Pa­ris-Lo­dron Uni­ver­si­tät Salz­burg

An­tia­po­p­to­tic func­tion of p21 re­gar­ding its sub­cel­lu­lar lo­ca­liza­t­i­on in As203 in­du­ced apo­pto­sis in CLL

Ganghammer Sylvia

Paris-Lodron Universität Salzburg

Regulation of chemokine-mediated VLA-4-activation in chronic lymphocytic leukemia

2015

Rebhandel Stefan

Paris-Lodron Universität Salzburg

DNA deamination in chronic lymphocytic leukemia (CLL), AID and APOBEC3 as sources of genomic damage

Huemer Michael

Paris-Lodron Universität Salzburg

The significance of the activation-induced cytidine deaminase in the clonal evolution of chronic lymphocytic leukemia and its abundance, localization and activity

Hufnagl Clemens

Paris-Lodron Universität Salzburg

Evaluation of circulating cell free DNA as a molecular monitoring tool during cancer therapy

2014

Grös­sin­ger Eva

Pa­ris-Lo­dron-Uni­ver­si­tät Salz­burg

The role of ion chan­nels in CLL

2013

Kocher Thomas

Paracelsus Medizinische Privatuniversität Salzburg

Immune Interactions in Chronic Lymphocytic Leukemia

Girbl Tamara

Paris-Lodron-Universität Salzburg

The microenvironmental regulation of adhesion and migration in chronic lymphocytic leukemia

2012

Brachtl Gabriele

Paris-Lodron Universität Salzburg

The involvement of CD38 and VLA-4 in migration, survival and proliferation of B chronic lymphocytic leukemia cells

Gas­s­ner Franz

Pa­ris-Lo­dron Uni­ver­si­tät Salz­burg

T cells in chro­nic lym­pho­cy­tic leu­ka­e­mia dis­play an ex­hausted phe­no­ty­pe and im­pai­red func­tio­na­li­ty that can be res­to­red by che­mo­the­ra­py.

Weiss Lukas

Paracelsus Medizinische Privatuniversität Salzburg

The duality of t-cells in chronic lymphocytic leukemia.

2010

Wacht Nathalie

Paris-Lodron Universität Salzburg

Novel substances for high risk CLL patients „CLL1“ – a promising option.

Ass­la­ber Da­nie­la

Pa­ris-Lo­dron Uni­ver­si­tät Salz­burg

Mi­croR­NAs in the Pa­tho­lo­gy of B-Cell Chro­nic Lym­pho­cy­tic Leu­ke­mia.

Olivier Angelika

Leopold-Franzens Universität Innsbruck

The Chemokine Network: CCL27/ CTACK in Multiple Myeloma and Implications in Immune Cell Function.

Maiz­ner Eva

Leo­pold-Fran­zens Uni­ver­si­tät Inns­bruck

Ex­pres­si­on pro­files of PKB/AKT iso­forms in mul­ti­ple mye­lo­ma.

2009

Hof­bau­er Se­bas­ti­an

Pa­ris-Lo­dron Uni­ver­si­tät Salz­burg

The Role of Pro­te­in Ki­nase B and Tcl1a in the Sur­vi­val of B – Chro­nic Lym­pho­cy­tic Leu­ke­mia Cells.

Desch Petra

Paris-Lodron Universität Salzburg

Cancer Stem Cells and Self-Renewal Pathways in B-Cell Chronic Lymphocytic Leukemia.

2008

Holler Claudia

Paris-Lodron Universität Salzburg

The Role of T cell receptor and B cell receptor characteristics in B cell chronic lymphocytic leukaemia (CLL).

Gry­sh­chen­ko Irina

Pa­ra­cel­sus Me­di­zi­ni­sche Pri­vat­uni­ver­si­tät Salz­burg

Rolle des SNP309 im Pro­mo­tor von MDM2 und p53 Sta­tus bei chro­nisch lym­pha­ti­sche Leuk­ämie (B-CLL).

Melchardt Thomas

Paracelsus Medizinische Privatuniversität Salzburg

New Drugs for high risk B-CLL patients: Screening of plant and microbe derived compounds.

2004

An­ether Ga­brie­le

Leo­pold-Fran­zens Uni­ver­si­tät Inns­bruck

Apo­p­to­ti­sche und an­tia­po­p­to­ti­sche Si­gna­le und deren me­di­ka­men­tö­sen Be­ein­flus­sung der B-Zell chro­nisch lym­pha­ti­schen Leuk­ämie.